Mk-3475-937- A Phase 3 Double-Blinded, Two-Arm Study To Evaluate The Safety And Efficacy Of Pembrolizumab (Mk-3475) Versus Placebo As Adjuvant Therapy In Participants With Hepatocellular Carcinoma And Complete Radiological Response After Surgical Resectio
Posted Date: Nov 24, 2020
- Investigator: Davendra Sohal
- Specialties: Cancer, Oncology
- Type of Study: Drug
This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary outcomes measured in this study are recurrence free and overall survival.
Criteria:
To Be Eligible: Must Have Diagnosis Of Hcc By Radiological Criteria And/Or Pathological Confirmation, Ecog 0-1, Child-Pugh Class A Liver Score Of 5 To 6 Points, Controlled Hepatitis B, Adequate Organ Function Per Protocol, No Prior Systemic Anti-Cancer Therapy For Hcc, No Organ Transplant, No Hypersensitivity To Study Drugs Or Excipients, No Active Or History Of Severe Co-Morbidity Or Infection That May Impact Patient Safety Or Study Results
Keywords:
Hepatocellular Carcinoma, Hcc
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com